Impact of tumour burden on chemotherapy-induced nausea and vomiting

British Journal of Cancer

Volumn 74, Issue 7, 1996, Pages 1114-1119

  Hursti, T J ^a,b   Avall Lundqvist E ^c   Borjeson S ^c   Fredrikson, M ^b   Furst C J ^c   Steineck, G ^c   Peterson, C ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Delayed emesis; Mechanisms; Tumour burden

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; ONDANSETRON; PLACEBO;

ADULT; AGED; ARTICLE; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; VOMITING;

EID: 0029744425     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.499     Document Type: Article

References (35)

1. AHLBOM A. (1990). Biostatistik för epidemiologer (Biostatistics for Epidemiologists). Studentlitteratur: Lund.
2. ALBERTS DS, DAHLBERG S, GREEN SJ, GARCIA D, HANNIGAN EV, O'TOOLE R, STOCK NOVACK D, SURWIT EA, MALVIYA VK AND JOLLES CJ. (1993). Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin cyclophosphamide versus carboplatin - cyclophosphamide in stages III (suhoptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer, 71, 618-627.
3. ANDREWS PLR AND DAVIS CJ. (1993). The mechanism of emesis induced by anti-cancer therapies. In Emesis in Anti-cancer Therapy, Mechanisms and Treatment, Andrews PLR and Sanger CJ. (eds) pp. 113-161. Chapman & Hall: London.
4. ANDRYKOWSKI MA AND GREGG ME. (1992). The role of psychological variables in post-chemotherapy nausea: anxiety and expectation. Psychosom. Med., 54, 48-58.
5. ARTINIAN NT, DUGGAN C AND MILLER P. (1993). Age differences in patient recovery patterns following coronary artery bypass surgery. Am. J. Crit. Care, 2, 453-461.
6. BORCOVEC TD. (1976). Physiological and cognitive processes in the regulation of anxiety. In Consciousness and Self-regulation. Advances in Research, Schwartz GE and Shapiro S. (eds) pp. 261-312. Plenum Press: New York.
7. CARMICHAEL J, BESSEL EM, HARRIS AL, HUTCHEON AW, DAWES PJ AND DANIELS S. (1994). Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. Br. J. Cancer, 70, 1161-1164.
8. DE WET M, FALKSON G AND RAPOPORT BL. (1993). Repeated use of granisetron in patients receiving cytostatic agents. Cancer. 71, 4043-4049.
9. DU BOIS A, MEERPOHL HG, VACH W, KOMMOSS FG, FENZL E AND PFLEIDERER A. (1992). Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur. J. Cancer, 28, 450-457.
10. ERSCHLER WB AND BALDUCCI L. (1994). Treatment considerations for older patients with cancer. In Vivo, 8, 737-744.
11. EYSENCK HJ AND EYSENCK SBG. (1964). Manual of the Eysenck Personality Inventory. University of London Press: London.
12. FREDRIKSON M, HURSTI T, FURST CJ, STEINECK G, BORJESON S, WIKBLOM M AND PETERSON C. (1992). Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion. Br. J. Cancer, 65, 779-780.
13. FREDRIKSON M, HURSTI T, STEINECK G, FÜRST CJ, BÖRJESON S AND PETERSON C. (1994). Delayed emesis of chemotherapy is augmented by high levels of endogenous noradrenaline. Br. J. Cancer, 70, 642-645.
14. FÜRST CJ, JOHANSSON S, FREDRIKSON M, HURSTI T, PETERSON C AND STEIN ECK G. (1992). Control of cisplatin induced emesis - a multidisciplinary intervention strategy. Med. Oncol. Tumor Pharmacother., 9, 81-86.
15. GANDARA DR, HARVEY WH, MONAGHAN GG, PEREZ EA AND HESKETH PJ. (1993). Delayed emesis following high-dose cisplatin: a double-blind randomised comparitive trial of ondansetron (GR 38032F) versus placebo. Eur. J. Cancer, 29A (suppl. 1), S35-S38.
16. GREENLAND S AND ROBINS JM. (1985). Estimation of a common effect parameter from sparse follow-up data. Biometrics, 41, 55-68.
17. HERON JF, GOEDHALS L, JORDAAN JP, CUNNINGHAM J AND CEDAR E. (1994). Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. Ann. Oncol., 5, 579-584.
18. HURSTI TJ, FREDRIKSON M, BÖRJESON S, FÜRST CJ, PETERSON C AND STEINECK G. (1992). Association between personality characteristics and the prevalence and extinction of conditioned nausea after chemotherapy. J. Psychosoc. Oncol., 10, 59-77.
19. HURSTI TJ, FREDRIKSON M, STEINECK G, BORJESON S, FURST CJ AND PETERSON C. (1993). Endogenous cortisol exerts antiemetic effect similar to that of exogenous corticosteroids. Br. J. Cancer, 68, 112-114.
20. HURSTI TJ, FREDRIKSON M, STEINECK G, BÖRJESON S, FÜRST CJ AND PETERSON C. (1994). Factors modifying the risk of acute and conditioned nausea and vomiting in ovarian cancer patients. Int. J. Oncol., 4, 695-701.
21. ITALIAN GROUP FOR ANTIEMETIC RESEARCH. (1993). Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J. Clin. Oncol., 11, 2396-2404.
22. ITALIAN GROUP FOR ANTIEMETIC RESEARCH. (1994). Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Ann. Oncol., 5, 585-589.
23. JOSS RA, BACCHI M, BUSER K, KIRCHNER V, NEUENSCHWANDER H, ORTH B, AAPRO MS AND THURLIMANN B. (1994). Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol., 5, 253-258.
24. KAIZER L, WARR D, HOSKINS P, LATREILLE J, LOFTERS W, YAU J, PALMER M, ZEE B, LEVY M AND PATER J. (1994). Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 12, 1050-1057.
25. LINDLEY CM, BERNARD S AND FIELDS SM. (1989). Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J. Clin. Oncol., 7, 1142-1149.
26. MARTIN M AND DIAZ-RUBIO E. (1990). Emesis during pregnancy: a new factor in chemotherapy induced emesis. Ann. Oncol., 1, 152-153.
27. MORROW GR. (1985). Effect of susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer, 55, 2766-2770.
28. O'BRIEN BJ, RUSTHOVEN J, ROCCHI A, LATREILLE J, FINE S, VANDENBERG T AND LABERGE F. (1993). Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres. Can. Med. Assoc. J., 149, 296-302.
29. PENNINGS JL, BACHULIS BL, SIMONS CT AND SLAZINSKI T. (1993). Survival after severe brain injury in the aged. Arch. Surg., 128, 787-794.
30. PETERSON C, HURSTI TJ, BÖRJESON S, ÅVALL-LUNDQVIST E, FREDIKSON M, FÜRST CJ, LOMBERG H AND STEINECK G. (1996). Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. Supportive Care Cancer, 4.
31. ROILA F, BOSCHETTI E, TONATO M, BASURTO C, BRACARDA S, SASSI M, PICCIAFUOCO M, PATOIA L, PENZA O, BALLATORI E AND DEL FAVERO A. (1991). Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. Am. J. Clin. Oncol., 14, 238-242.
32. RUFF P, PASKA W, GOEDHALS L, POUILLART P, RIVIERE A, VOROBIOF D, BLOCH B, JONES A, MARTIN C, BRUNET R, BUTCHER M, FORSTER J AND MCQUADE B. (1994). Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group [published erratum appears in Oncology 51(3), 243]. Oncology, 51, 113-8.
33. SORBE B, HOGBERG T, HIMMELMANN A, SCHMIDT M, RAISANEN I, STOCKMEYER M AND DE BRUIJN KM. (1994). Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy. Eur. J. Cancer, 30, 629-634.
34. SPIELBERGER CD, GORSUCH RL AND LUSHENE R. (1968). The-State Trait Anxiety Inventory (STAI). Consulting Psychologists Press: Palo Alto, USA.
35. TONATO M, ROILA F AND DEL FAVERO A. (1991). Methodology of antiemetic trials: a review. Ann. Oncol., 2, 107-114.